

**Program for Cancerfondens Planeringsgrupp för Onkologisk Radionuklidterapi höstmöte 2017****Wednesday 15 nov**

<i>Time</i>	<i>Topic</i>	<i>Speaker</i>	<i>Affiliation</i>
12.00	Registration		
13.00	Welcome		
<b>Prostate Cancer Theranostics - Clinical and Preclinical      Chair: Sven-Erik Strand</b>			
13.15	Prostate cancer – clinical challenge	Anders Bjartell	Lund University
14.00	Imaging with a purpose: From Diagnostics to Theranostics  From NUCLEAR RADIOLOGY TO NUCLEAR MEDICINE	Johannes Czernin	UCLA
14.45	Coffee, Tea and Fruits		
15.00	PSMA Prostanostics in Clinical Routine	Kalevi Kairemo	Docrates Cancer Center Helsinki
15.30	Dosimetry in Prostate Cancer therapy	Michael Lassmann	University Hospital Würzburg
16.00	Establishing 177Lu-PSMA-617 radioligand therapy in syngeneic in vivo models of prostate cancer	Susan Evans-Axelsson	Lund University
16.15	Bayer		
16.25	Short break		
16.40	Targeting Secreted Antigens for Precision Imaging and Therapy	David Ulmert	MSKCC
17.25	Radioimmunotherapy efficacy assessment of an internalizing humanized antibody: a systemic and tumor micro dosimetry perspective on a secreted antigen, hk2	Oskar Vilhelmsson-Timmermand	Lund University
17.40	Stem cells in Prostate Cancer	Jens Ceder	Lund University
17.55	Concluding remarks and future aspects	Anders Bjartell	Lund University
18.10	Adjourn and light snacks		

Thursday 16 nov

<i>Time</i>	<i>Topic</i>	<i>Speaker</i>	<i>Affiliation</i>
<b>Radiobiology Chair: Bo Stenerlöv</b>			
08.30	Biological Dosimetry in Nuclear Medicine	Michael Lassmann, Presenting work by Uta Eberlein	University Hospital Würzburg
09.00	$\alpha$ 1-microglobulin (A1M) - a radical scavenger with potential to be used for radiation protection	Magnus Gram	Lund University
9.30	Protection of kidney function with human recombinant $\alpha$ 1-microglobulin (A1M) in a mouse radiation therapy model	Jonas Ahlstedt	Lund University
9.45	The role of chromatin in response to alpha and gamma radiation in breast cancer cells	Lovisa Lundholm	Stockholm University
10.00	Evaluation of the correlations between the absorbed bone marrow dose and bone marrow response during the first cycle of $^{177}\text{Lu}$ -DOTATATE treatment	Linn Hagmarker	Gothenburg University
10.15	Coffee, Tea and Fruits		
10.45	Age and sex: important variables in biomarker discovery for radiotherapy and risk estimation	Britta Langen	Gothenburg University
11.00	The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer	Bertil Persson	Lund University
11.15	A1M-Pharma		
11.25	Perkin Elmer		
11.35	Short break		
<b>Imaging &amp; Dosimetry Chair: Eva Forsell-Aronsson</b>			
11.45	Ongoing work on radionuclide therapy dosimetry in EANM, ICRP, ICRU och IAEA	Sören Mattsson and Katarina Sjögren- Gleisner	Lund University

12.00	Intratumoral activity distribution over time in preclinical radioimmunotherapy models	Anders Örbom	Lund University
12.15	Lund -Göteborg NET study	Katarina Sjögren-Gleisner	Lund University
12.35	Ridgeview		
12.45	Lunch		
14.00	New developments in SPECT and PET	Magnus Dahlbom	UCLA
14.45	PET in preclinical intratherapy monitoring	Emma Mellhammar	Lund University
15.00	Targeted Nanoparticles for theranostics of prostate cancer	Pontus Kjellman	Lund University
15.15	Magnetomotive ultrasound imaging - a new tool for cancer diagnosis	Maria Evertsson	Lund University
15.30	Simultaneous preclinical PET-MRI study of lymphatic drainage of chelator free <sup>64</sup> Cu-labeled nanoparticles	Renata Madru	Lund University
15.45	Coffee, Tea and Fruits		
16.00	Comparison of an analysis method and visual assessment concerning liver metastases in (111)In-octreotide SPECT imaging including Monte Carlo based reconstruction	Emma Wikberg	Sahlgrenska University Hospital
16.15	A method for <sup>177</sup> Lu-PRRT tumour dosimetry based on hybrid planar-SPECT/CT images and semi-automatic segmentation	Daniel Roth	Lund University
16.30	High-resolution Alpha Camera imaging as a tool for developing Targeted Alpha Therapy	Tom Bäck	Gothenburg University
16.45	GENOVIS		
16.55	MoleCubes		
18.30	Conference Dinner (Only for those who registered to attend the dinner)		

Friday 17 nov

<i>Time</i>	<i>Topic</i>	<i>Speaker</i>	<i>Affiliation</i>
<b>Radiochemistry, Poster and Lund Future Science Chair: Katarina Sjögreen-Glesiner</b>			
09.00	Radiochemistry and Cyclotron produced radionuclides	Tomas Ohlsson	Lund University
09.30	Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy	Anja Mortensen	Uppsala University
09.45	Affibody-based PNA-mediated pretargeted therapy	Mohamed Altai	Uppsala University
10.00	Poster presentations		
10.30	ImaGene-iT		
10.40	SAM-Nordic		
10.50	Coffee, Tea and Fruits		
<b>Lund future Science</b>			
11.05	Introduction to the European Spallation Source ESS	Mats Lindroos	Lund University
11.35	MAX IV – Synchrotron Light Source	Martin Beck	Lund University
12.05	JNMMI Editors view on future research and publications	Johannes Czernin	UCLA
12.50	Best Young Scientist's Presentation, Announcement of Next Meeting and Adjourn	Eva Forsell-Aronsson	Gothenburg University



## Posters

<i>Title</i>	<i>Author</i>	<i>Affiliation</i>
Monte Carlo-based SPECT reconstruction for absorbed-dose estimation in treatments with 90Y-microspheres	Johan Gustafsson	Lund University
Autoradiography and biopsy measurements of a resected hepatocellular carcinoma treated with 90Y radioembolization demonstrates large absorbed dose heterogeneities	Jens Hemmingsson	Gothenburg University
The novel GlyCLICK conjugation technology allows site-specific and quantitative labeling of antibodies for in vivo and in vitro imaging	Hanna Toftevall	Genovis AB
DNA damage and repair after a combined exposure to alpha particles and X-rays	Andrzej Wojcik	Stockholm University
Therapeutic potential of Lu-177-octreotate for neuroblastoma – preclinical studies	Arman Romiani	Gothenburg University
In vitro screening for Lu-177-octreotate uptake in human tumor cell lines	Sofia Saadati	Gothenburg University

## Our commercial partners



Science For A Better Life

